Promising cancer combo trial halted after just 2 patients
NCT ID NCT06939036
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested a radioactive drug called 225Ac-SSO110 combined with standard immune checkpoint inhibitors for people with advanced small cell lung cancer or Merkel cell carcinoma. The goal was to check safety and find the right dose. However, the trial was terminated early after enrolling only 2 participants, so no meaningful results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
225Ac-SSO110 (a radioactive drug) plus standard immune checkpoint inhibitors
What this could lead to
If it had worked, this could have pointed toward a new treatment option for people with advanced lung or skin cancer.
What could go wrong
The trial was terminated early with only 2 participants enrolled, so no conclusions can be drawn. The approach is very early-stage and may not be safe or effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MERKEL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Biogenix Molecular
Miami, Florida, 33165, United States
-
GenesisCare
Alexandria, Australia
-
John Theurer Cancer Center at Hackensack UMC
Hackensack, New Jersey, 07601, United States
-
UPMC
Pittsburgh, Pennsylvania, 15219, United States
-
United Theranostics
Glen Burnie, Maryland, 21061, United States
-
University of Louisville Health-Brown Cancer Center
Louisville, Kentucky, 40202, United States
-
Virginia Cancer Specialists, PC
Fairfax, Virginia, 22031, United States